BNB Plus Corp. shifts focus to blockchain, AI infrastructure

BNB Plus Corp. has announced a significant strategic transition aimed at redefining its operational focus. The company will move away from its previous model as a digital asset treasury and will now concentrate on building infrastructure for blockchain and agentic AI technologies.

This shift is crucial as BNB Plus Corp. seeks to adapt to the evolving landscape of financial services, where the demand for robust technological infrastructure is increasing. The company aims to provide the necessary tools and services for financial institutions and enterprises to effectively utilize these emerging technologies.

Background

BNB Plus Corp., trading under the ticker BNBX on the OTCQB Venture Market, is incorporated in Delaware and operates within the Finance Services sector (SIC: 6199). The company has undergone several name changes in its history, previously known as Applied DNA Sciences, Inc. and ProHealth Medical Technologies Inc. BNB Plus Corp. has been actively filing reports with the SEC, with its most recent filings including an 8-K on October 2, 2026.

What the Filing Says

In its recent SEC filing, BNB Plus Corp. stated, "On October 2, 2026, BNB Plus Corp. issued a press release announcing its strategic transition." The company plans to transition from a digital asset treasury model to operating infrastructure supporting blockchain and AI applications. This change reflects a broader industry trend towards integrating technology into financial services.

Impact

This strategic shift may significantly affect various stakeholders, including financial institutions looking to adopt blockchain and AI technologies. By focusing on infrastructure, BNB Plus Corp. aims to meet the growing demand for secure and compliant solutions in the financial services industry.

What's Next

The filing does not say what happens next. However, BNB Plus Corp. is evaluating options to strengthen its subsidiary, LineaRx, which specializes in genetic medicines, indicating potential future developments in both the biotechnology and technology infrastructure sectors.